AIMS: To evaluate the effects of longitudinal patterns and types of non-injection drug use (NIDU) on HIV progression in the highly active antiretroviral therapy (HAART) era. DESIGN: Women's Interagency HIV Study (WIHS), a prospective cohort study conducted at six US sites. METHODS: Data were collected semi-annually from 1994 to 2002 on 1046 HIV(+) women. Multivariate Cox proportional hazards modeling was used to estimate relative hazards for developing AIDS and for death by pattern and type of NIDU. FINDINGS: During follow-up, 285 AIDS events and 287 deaths, of which 177 were AIDS-related, were reported. At baseline, consistent and former NIDU was associated with CD4(+) counts of < 200 cells/microl (43% and 46%, respectively) and viral load > 40,000 copies/ml (53% and 55%, respectively). Consistent NIDU reported less HAART use (53%) compared with other NIDU patterns. Stimulant use was associated with CD4(+) cell counts of < 200 cells/microl (53%) and lower HAART initiation (63%) compared with other NIDU types. In multivariate analyses, progression to AIDS was significantly higher among consistent (RH = 2.52), inconsistent (RH = 1.63) and former (RH = 1.56) users compared with never users; and for stimulant (RH = 2.04) and polydrug (RH = 1.65) users compared with non-users. Progression to all-cause death was higher only among former users (RH = 1.48) compared with never users in multivariate analysis. NIDU behaviors were not associated with progression to AIDS-related death. CONCLUSIONS: In this study, pattern and type of NIDU were associated with HIV progression to AIDS and all-cause mortality. These differences were associated with lower HAART utilization among consistent NIDU and use of stimulants, and poor baseline immunological and virological status among former users.
AIMS: To evaluate the effects of longitudinal patterns and types of non-injection drug use (NIDU) on HIV progression in the highly active antiretroviral therapy (HAART) era. DESIGN:Women's Interagency HIV Study (WIHS), a prospective cohort study conducted at six US sites. METHODS: Data were collected semi-annually from 1994 to 2002 on 1046 HIV(+) women. Multivariate Cox proportional hazards modeling was used to estimate relative hazards for developing AIDS and for death by pattern and type of NIDU. FINDINGS: During follow-up, 285 AIDS events and 287 deaths, of which 177 were AIDS-related, were reported. At baseline, consistent and former NIDU was associated with CD4(+) counts of < 200 cells/microl (43% and 46%, respectively) and viral load > 40,000 copies/ml (53% and 55%, respectively). Consistent NIDU reported less HAART use (53%) compared with other NIDU patterns. Stimulant use was associated with CD4(+) cell counts of < 200 cells/microl (53%) and lower HAART initiation (63%) compared with other NIDU types. In multivariate analyses, progression to AIDS was significantly higher among consistent (RH = 2.52), inconsistent (RH = 1.63) and former (RH = 1.56) users compared with never users; and for stimulant (RH = 2.04) and polydrug (RH = 1.65) users compared with non-users. Progression to all-cause death was higher only among former users (RH = 1.48) compared with never users in multivariate analysis. NIDU behaviors were not associated with progression to AIDS-related death. CONCLUSIONS: In this study, pattern and type of NIDU were associated with HIV progression to AIDS and all-cause mortality. These differences were associated with lower HAART utilization among consistent NIDU and use of stimulants, and poor baseline immunological and virological status among former users.
Authors: D C Des Jarlais; S R Friedman; M Marmor; H Cohen; D Mildvan; S Yancovitz; U Mathur; W el-Sadr; T J Spira; J Garber Journal: AIDS Date: 1987-07 Impact factor: 4.177
Authors: Kathryn Anastos; Yolanda Barrón; Paolo Miotti; Barbara Weiser; Mary Young; Nancy Hessol; Ruth M Greenblatt; Mardge Cohen; Michael Augenbraun; Alexandra Levine; Alvaro Muñoz Journal: Arch Intern Med Date: 2002-09-23
Authors: Mardge H Cohen; Audrey L French; Lorie Benning; Andrea Kovacs; Kathryn Anastos; Mary Young; Howard Minkoff; Nancy A Hessol Journal: Am J Med Date: 2002-08-01 Impact factor: 4.965
Authors: Lucy E Wilson; David L Thomas; Jacqueline Astemborski; Terri L Freedman; David Vlahov Journal: J Infect Dis Date: 2002-05-31 Impact factor: 5.226
Authors: Tanyka Suzanne Sam; Heidi E Hutton; Bryan Lau; Mary E McCaul; Jeanne Keruly; Richard Moore; Geetanjali Chander Journal: AIDS Behav Date: 2015-11
Authors: J F G Monteiro; D J Escudero; C Weinreb; T Flanigan; S Galea; S R Friedman; B D L Marshall Journal: Epidemiol Infect Date: 2016-01-12 Impact factor: 2.451
Authors: Adam W Carrico; Peter W Hunt; Torsten B Neilands; Samantha E Dilworth; Jeffrey N Martin; Steven G Deeks; Elise D Riley Journal: J Acquir Immune Defic Syndr Date: 2019-01-01 Impact factor: 3.731
Authors: Robert L Cook; Fang Zhu; Bea Herbeck Belnap; Kathleen Weber; Judith A Cook; David Vlahov; Tracey E Wilson; Nancy A Hessol; Michael Plankey; Andrea A Howard; Stephen R Cole; Gerald B Sharp; Jean L Richardson; Mardge H Cohen Journal: Am J Epidemiol Date: 2009-03-06 Impact factor: 4.897
Authors: Judith A Cook; Jane K Burke-Miller; Mardge H Cohen; Robert L Cook; David Vlahov; Tracey E Wilson; Elizabeth T Golub; Rebecca M Schwartz; Andrea A Howard; Claudia Ponath; Michael W Plankey; Alexandra M Levine; Andrea Levine; Dennis D Grey Journal: AIDS Date: 2008-07-11 Impact factor: 4.177